Sixteen years ago, Paul Yock, MD, an innovative interventional cardiologist, created what’s now known as the Stanford Byers Center for Biodesign to teach something that many saw as something that couldn’t be taught.
In this interview with Medtech Talk, Dr. Yock recalls that some believed, “Innovation is the playground of the unusually gifted and you can’t make a practice or a discipline out of it.”
The center went on to do just that, tilling the soil that helped nurture start-ups like Oculeve, which created a device to treat dry eye that received FDA approval just this week. (Allergan acquired the company two years ago.)
The center’s teachings have become even more critical as the forces dragging on Medtech innovation grow even more complex.
“Unlike consumer product innovation, Medtech doesn’t have a single customer,” Dr. Yock explains. “You have a very complicated matrix of stakeholders, all of whom have interest in new technology,” including patients, providers, and payers.
In this podcast, Dr. Yock shares his insights on Medtech innovation, explains the impact financial pressures have had on new creation, and offers his take on Google and Apple making a run on developing Medtech devices.